-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trabedersen in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trabedersen in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trabedersen in Solid Tumor Drug Details: Trabedersen (OT-101) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZD-100 in Resistant Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZD-100 in Resistant Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZD-100 in Resistant Hypertension Drug Details: ZD-100 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Motixafortide Acetate in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Motixafortide Acetate in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Motixafortide Acetate in Pancreatic Ductal Adenocarcinoma Drug Details: Motixafortide is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Ewing Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Ewing Sarcoma Drug Details: Regorafenib (BAY 73-4506, Stivarga) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Chondrosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Chondrosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Chondrosarcoma Drug Details: Regorafenib (BAY 73-4506, Stivarga) is an anti-neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Soft Tissue Sarcoma Drug Details: Regorafenib (BAY 73-4506,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Pancreatic Ductal Adenocarcinoma Drug Details: Regorafenib (BAY 73-4506, Stivarga)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Liposarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Liposarcoma Drug Details: Regorafenib (BAY 73-4506, Stivarga) is an anti-neoplastic agent....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Anaplastic Astrocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Anaplastic Astrocytoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Anaplastic Astrocytoma Drug Details: Regorafenib (BAY 73-4506, Stivarga) is an...